Additional information
| Trade Name | SANDOSTATIN LAR |
|---|---|
| Generic Name | Octreotide |
| Manufacturer | Novartis India Ltd |
| Drug Type | Oncology |
| Indication | pancreatic cancer |
| Doasage Form | Injectible |
| Packaging | 1 X 1 prefilled syringe of 2ml |
Sandostatin® (Octreotide Acetate), a hormone drug, suppresses the secretion of growth hormone (GH), and in many cases suppresses insulin-like growth hormone-1 (IGF-1) (somatomedin C).
Classified as a somatostatin analog is indicated for long-term treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors such as carcinoid, pancreatic islet cell tumors, gastrinoma, or vasoactive intestinal peptide-secreting tumors (VIPomas) and long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate-release. It is also used to treat acromegaly when the body produces too much growth hormone, and the hands, feet, face, or head grow too large.
| Trade Name | SANDOSTATIN LAR |
|---|---|
| Generic Name | Octreotide |
| Manufacturer | Novartis India Ltd |
| Drug Type | Oncology |
| Indication | pancreatic cancer |
| Doasage Form | Injectible |
| Packaging | 1 X 1 prefilled syringe of 2ml |